Additional file 1:Table S1. of A somatization comorbidity phenotype impacts response to therapy in rheumatoid arthritis: post-hoc results from the certolizumab pegol phase 4 PREDICT trial

SCP categories and medical history/diagnoses at baseline, with missing data handled by non-responder imputation (NRI). Table S2. Patients withdrawn from the study at/before and after week 12 due to lack of efficacy. Figure S1. Mean DAS28(ESR) score by SCP status, with missing data handled by last observation carried forward (LOCF). Full analysis set. (DOCX 1302 kb)